» Articles » PMID: 27847671

Heavy Alcohol Drinking Associated Akathisia and Management with Quetiapine XR in Alcohol Dependent Patients

Overview
Journal J Addict
Date 2016 Nov 17
PMID 27847671
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Heavy drinking contributes to involuntary body movements such as akathisia. Quetiapine has been shown to alleviate symptoms of akathisia; however, its efficacy in the alcohol dependent population is not well established. Thus, we aimed to identify efficacy of Quetiapine in treating akathisia in very heavy drinking alcohol dependent patients. 108 male and female heavy alcohol consuming study participants received 13 weeks of Quetiapine XR. Drinking history (Timeline Followback, TLFB), depression (Montgomery-Asberg Depression Rating Scale, MADRS), and movement (Barnes Akathisia Scale, BARS) measures were collected at baseline (0 W), week 6 (6 W), and week 12 (12 W). The role of drinking, symptoms of depression, and efficacy of Quetiapine for treating akathisia were assessed. In patients with no symptoms of depression (low MADRS), Quetiapine treatment decreased symptoms of akathisia. Patients with clinically significant depression (high MADRS) reported a significant increase in akathisia measures at 6 W which eventually decreased at 12 W to below baseline levels. The increase in akathisia at 6 W corresponded with a significant increase in the patients' total drinks and heavy drinking pattern. Treatment with Quetiapine progressively lowered the occurrence of akathisia in alcohol dependent patients who do not show symptoms of depression. Quetiapine treatment lowered akathisia over time in heavy drinkers who had clinically significant symptoms of depression.

Citing Articles

Diagnostic Prospectives with Tau Protein and Imaging Techniques to Detect Development of Chronic Traumatic Encephalopathy.

Naskar A, Jayanty D, Head K, Khanna G, Vatsalya V, Banerjee A J Behav Brain Sci. 2023; 13(4):55-65.

PMID: 37275219 PMC: 10239269. DOI: 10.4236/jbbs.2023.134005.


Dopamine-receptor blocking agent-associated akathisia: a summary of current understanding and proposal for a rational approach to treatment.

Musco S, McAllister V, Caudle I Ther Adv Psychopharmacol. 2020; 10:2045125320937575.

PMID: 32922732 PMC: 7457694. DOI: 10.1177/2045125320937575.


Medications for alcohol use disorders: An overview.

Akbar M, Egli M, Cho Y, Song B, Noronha A Pharmacol Ther. 2017; 185:64-85.

PMID: 29191394 PMC: 5898984. DOI: 10.1016/j.pharmthera.2017.11.007.


Sex differences in the association of alcohol with cognitive decline and brain pathology in a cohort of octogenarians.

Wardzala C, Murchison C, Loftis J, Schenning K, Mattek N, Woltjer R Psychopharmacology (Berl). 2017; 235(3):761-770.

PMID: 29185023 PMC: 5839119. DOI: 10.1007/s00213-017-4791-6.

References
1.
Mostile G, Jankovic J . Alcohol in essential tremor and other movement disorders. Mov Disord. 2010; 25(14):2274-84. DOI: 10.1002/mds.23240. View

2.
Sobell L, Agrawal S, Sobell M, Leo G, Young L, Cunningham J . Comparison of a quick drinking screen with the timeline followback for individuals with alcohol problems. J Stud Alcohol. 2004; 64(6):858-61. DOI: 10.15288/jsa.2003.64.858. View

3.
Bartels M, Heide K, Mann K, Schied H . Treatment of akathisia with lorazepam. An open clinical trial. Pharmacopsychiatry. 1987; 20(2):51-3. DOI: 10.1055/s-2007-1017074. View

4.
Demirkiran M, Jankovic J . Paroxysmal dyskinesias: clinical features and classification. Ann Neurol. 1995; 38(4):571-9. DOI: 10.1002/ana.410380405. View

5.
Koller W, Graner D, Mlcoch A . Essential voice tremor: treatment with propranolol. Neurology. 1985; 35(1):106-8. DOI: 10.1212/wnl.35.1.106. View